Xspray Pharma (XSPRAY) Q1 2025 earnings summary

Executive summary

• No net sales in Q1 2025; focus remains on regulatory approval and launch preparation for DasynocⓇ in the US.

• Loss before tax improved to SEK -42.3 million from SEK -67.8 million year-over-year.

• Updated FDA application for DasynocⓇ submitted in April 2025; launch targeted for autumn 2025.

• Interim data for XS003 nilotinib showed stable bioavailability, supporting HyNap™ technology benefits.

Financial highlights

• Net sales: SEK 0 thousand (unchanged year-over-year).

• Loss before tax: SEK -42,321 thousand (improved from -67,781 thousand year-over-year).

• Earnings per share before dilution: SEK -1.14 (improved from -2.17 year-over-year).

• Cash and cash equivalents: SEK 125,725 thousand (up from SEK 104,155 thousand year-over-year).

• Cash flow from operating activities: SEK -66,329 thousand (down from -55,311 thousand year-over-year).

Outlook and guidance

• FDA decision on DasynocⓇ expected within 2–4 weeks of resubmission; launch planned for autumn 2025.

• Application for XS003 nilotinib market approval planned for summer 2025.

• Financing expected to cover capital needs until DasynocⓇ approval and completion of XS003 studies; debt financing being explored for launch.